Antithrombotic Therapy for Venous Thromboembolism

Venous thromboembolism (VTE) includes superficial and deep vein thrombosis of the leg or pelvis and pulmonary embolism (PE).¹ VTE affects an estimated 600 000 people in the US, with approximately 60 000 to 100 000 people dying from VTE and PE annually.² Despite its prevalence, 25% to 40% of all VTE events are idiopathic, making diagnosis and prevention difficult.¹